STOCK TITAN
  1. Home
  2. Sec-filings
  3. DTIL
  4. [Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity

Precision BioSciences (DTIL) counsel sells 8,854 shares in RSU tax trade

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Precision BioSciences (DTIL) reported insider equity activity by its General Counsel and Secretary, Dario Scimeca. On January 20, 2026, several tranches of Restricted Stock Units (RSUs) vested, resulting in the issuance of 1,978, 8,425 and 14,908 shares of common stock at an exercise price of $0 per share. These RSUs were granted in 2023 and 2024 and vest in three substantially equal annual installments, subject to continued service.

On January 21, 2026, Scimeca sold 8,854 shares of Precision BioSciences common stock at $4.03 per share in a transaction coded as a sale. According to the disclosure, this was a Rule 10b5-1 sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees arising from the RSU vesting. After these transactions, Scimeca directly held 44,715 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Scimeca Dario
Role General Counsel and Secretary
Sold 8,854 shs ($36K)
Type Security Shares Price Value
Sale Common Stock 8,854 $4.03 $36K
Exercise Restricted Stock Units 1,978 $0.00 --
Exercise Restricted Stock Units 8,425 $0.00 --
Exercise Restricted Stock Units 14,908 $0.00 --
Exercise Common Stock 1,978 $0.00 --
Exercise Common Stock 8,425 $0.00 --
Exercise Common Stock 14,908 $0.00 --
Holdings After Transaction: Common Stock — 44,715 shares (Direct); Restricted Stock Units — 0 shares (Direct)
Footnotes (1)
  1. Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 29, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scimeca Dario
(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E PETTIGREW STREET, SUITE A-100
(Street)
DURHAM NC 27701
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel and Secretary
3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/20/2026 M 1,978(1) A $0(2) 30,236 D
Common Stock 01/20/2026 M 8,425(1) A $0(2) 38,661 D
Common Stock 01/20/2026 M 14,908(1) A $0(2) 53,569 D
Common Stock 01/21/2026 S(3) 8,854 D $4.03 44,715 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 01/20/2026 M 1,978 (4) (4) Common Stock 1,978 $0 0 D
Restricted Stock Units (2) 01/20/2026 M 8,425 (5) (5) Common Stock 8,425 $0 8,425 D
Restricted Stock Units (2) 01/20/2026 M 14,908 (6) (6) Common Stock 14,908 $0 14,907 D
Explanation of Responses:
1. Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 29, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
4. On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
5. On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
6. On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Remarks:
/s/ Dario Scimeca 01/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DTIL disclose for Dario Scimeca?

Precision BioSciences (DTIL) disclosed that General Counsel and Secretary Dario Scimeca had RSUs vest on January 20, 2026, and sold 8,854 shares of common stock on January 21, 2026 at $4.03 per share.

Were the DTIL insider share sales by Dario Scimeca part of a 10b5-1 plan?

Yes. The filing states that the sales were effected under a Rule 10b5-1 plan adopted on September 29, 2025, and were executed as a sell-to-cover for tax withholding on vested RSUs.

How many Precision BioSciences shares did Dario Scimeca own after the reported transactions?

Following the reported RSU vesting and the sell-to-cover transaction, Dario Scimeca directly held 44,715 shares of Precision BioSciences common stock.

What RSUs vested for DTIL General Counsel Dario Scimeca on January 20, 2026?

On January 20, 2026, RSU awards covering 1,978, 8,425, and 14,908 underlying shares vested, each RSU representing the right to receive one share of Precision BioSciences common stock.

What are the vesting terms of Dario Scimeca’s RSU grants at Precision BioSciences?

The RSU grants from January 20, 2023, April 18, 2024, and August 22, 2024 vest in three substantially equal annual installments, beginning on either January 20, 2024 or January 20, 2025, subject to continued service.

Did Dario Scimeca sell DTIL shares for reasons other than taxes?

No. The disclosure explains that the transaction was a sell-to-cover, with shares sold only to cover tax withholding obligations and fees related to RSU vesting and settlement.